Ex vivo expansion of early and late megakaryocyte progenitors

Area of Science:

• Hematology
• Cell Biology
• Biotechnology

Background:

• Megakaryocytes (MK) are crucial for platelet production.
• Ex vivo expansion of MKs from peripheral blood progenitor cells (PBPCs) is a potential strategy to supplement autografts.
• Understanding MK differentiation kinetics is vital for optimizing ex vivo expansion protocols.

Purpose of the Study:

• To evaluate the megakaryocytopoietic productivity of serum-free in vitro cultures of human CD34+ cells.
• To assess the impact of specific growth factors, including MGDF, SCF, and G-CSF, on MK expansion and differentiation.
• To determine the optimal culture duration for generating MKs with potential for in vivo platelet production.

Main Methods:

• Small-scale, serum-free in vitro cultures of human CD34+ cells were established.
• Cultures were supplemented with MK growth and development factor (MGDF) and stem cell factor (SCF), with or without G-CSF.
• Characterization involved flow cytometry and clonogenic assays at multiple time points (3, 6, 9, and 13 days).

Main Results:

• CD34+ cells showed significant expansion (5.2-fold at day 6, 3.4-fold at day 9).
• CD41+ cells and Colony-forming unit-megakaryocyte (CFU-MK) expanded exponentially, but the proportion of primitive CFU-MK decreased over time.
• G-CSF increased total cell expansion but reduced CD41+ cell frequency, offering no net gain in MK production.
• PB CD34+ cells cultured for 3-6 days were enriched in primitive MK progenitors, while 9-13 days yielded more differentiated MKs.

Conclusions:

• The combination of MGDF and SCF is sufficient for expanding CD34+/CD41+ cells ex vivo.
• The maturity stage of ex vivo-expanded MKs that is most conducive to optimal in vivo platelet production remains to be determined.
• A clinical trial is planned to investigate the efficacy of ex vivo-expanded MKs on platelet recovery based on their differentiation stage.